Skip to main content
Frontiers in Nutrition logoLink to Frontiers in Nutrition
. 2026 Jan 14;13:1758803. doi: 10.3389/fnut.2026.1758803

A novel corrected anion gap links metabolic acid attack to peptic ulcer disease

Xian-Ping Lin 1,*, Song-Xing Lin 2
PMCID: PMC12846972  PMID: 41613014

Abstract

Background

Physiological evidence indicates that systemic acid-base balance may be associated with gastric acid secretion, which is a key factor in peptic ulcers disease (PUD). However, the epidemiological relationship of this association with PUD risk remains unclear.

Aim

This study investigates a novel corrected anion gap (AGcorr, reflecting metabolic acid load) and bicarbonate (HCO₃, reflecting alkaline reserve) in relation to PUD.

Methods

This retrospective case-control study analyzed endoscopy-confirmed 64 PUD patients and 541 non-PUD controls with normal hepatic and renal function from a Fujian tertiary hospital (Jan 2023–Jun 2025). The anion gap (AG) was corrected to fully-corrected AGcorr and albumin-corrected AG (ACAG). Four models (A: AGcorr; B: HCO₃; C: AG; D: ACAG) were adjusted for sex, age, and Na to study the relationships between AGcorr, ACAG, AG, HCO3, and PUD. Post-hoc power and sensitivity analysis were conducted.

Results

Model A showed that AGcorr was significantly positively associated with PUD risk (OR = 1.167, 95% CI: 1.050–1.298, P = 0.045), with a high statistical power of 89%. Sensitivity analysis with an expanded control group (n = 1915) confirmed a significant AGcorr-PUD association (OR = 1.138, 95% CI: 1.029–1.259, P = 0.012), with post hoc power of 0.81. The sensitivity analysis with case-control matching for sex and age showed that AGcorr remained significantly associated with PUD (P = 0.020). In contrast, Model C and Model D were both significantly correlated (P < 0.05) but showed poor fit (H-L P < 0.05). However, their statistical power differed, with values of only 0.64 and 0.84, respectively. Model B indicated a negative correlation between PUD and HCO₃ (OR = 0.894, 95% CI: 0.802–0.996, P = 0.043), but with low statistical power (65%) and instability in sensitivity analysis.

Conclusion

After adjusting for sex, age, and Na, AGcorr remained an independent risk factor for PUD in individuals with normal liver and kidney function. The fully-corrected AG outperformed both ACAG and uncorrected AG. Metabolic non-volatile acid attack may be an important pathogenic mechanism in PUD. HCO₃ may have a potential protective effect against PUD. The findings contribute to improving PUD care but require further validation in diverse groups.

Keywords: acid-base balance, anion gap, corrected anion gap, metabolic acid load, metabolic non-volatile acid, peptic ulcer disease, unmeasured anions

Introduction

Peptic ulcer disease (PUD) is a common clinical condition. An investigation spanning 1997 to 2005 reported a PUD incidence of 7.5% in the United Kingdom (1). More recent health survey data from 2017 to 2018 indicated that the prevalence of gastric and duodenal ulcers among Chinese adults aged 18–64 was 5.4% (3.9–7.3%) and 2.5% (1.7–3.7%), respectively (2). Helicobacter pylori (H. pylori), non-steroidal anti-inflammatory drugs (NSAIDs), gastric acid, and pepsin are recognized as the most significant aggressive factors in PUD (3–9). Current understanding of PUD risk focuses predominantly on gastric-localized elements and external triggers, with corresponding therapeutic strategies largely targeting these offenders (10–15). Yet, the role of metabolic acid load, originating from internal metabolic processes, has been largely overlooked. Excessive gastric acid secretion is a recognized invasive factor in PUD pathogenesis. The acid-secreting function of the gastric mucosa may also play a significant role in regulating metabolic acid–base balance. Evidence suggests a potential link between metabolic acid load and gastric hyperacidity in PUD (16, 17). A diet rich in sulfur-containing amino acids and low in fruits and vegetables can adversely affect acid–base balance, potentially leading to subclinical metabolic acidosis (18). Furthermore, normal physiological activities, particularly strenuous exercise, generate acidic metabolites such as lactic acid and ketone bodies.

Metabolic acidosis can be classified into two primary categories: increased load of metabolic acids (predominantly non-volatile acids) and excessive alkali loss. Clinically, the anion gap (AG) serves as an important indicator for assessing metabolic acid load, while bicarbonate (HCO₃) level is a key marker for evaluating alkali reserve. The AG represents the difference between undetermined anions (UA) and undetermined cations (UC) in plasma. When the AG value exceeds the normal range, it suggests a potential increase in non-volatile metabolic acid load, primarily stemming from non-volatile acid drugs, food sources or metabolic disorders, which generate these non-volatile acid products. This pattern is commonly observed in conditions like lactic acidosis and ketoacidosis (19–22). In such cases, because the excess H+ ions neutralize HCO₃, the measured HCO₃ level may appear normal or only slightly decreased. Conversely, in specific situations such as renal tubular acidosis or severe diarrhea leading to substantial HCO₃ loss, the metabolic acidosis is characterized primarily by HCO₃ depletion (23). Here, HCO₃ decreases significantly, and chloride (Cl) compensates electroneutrality, resulting in a normal AG. Additionally, acidic substances found in foods like carbonated beverages are easily metabolized and eliminated via respiration, while acetic acid (from vinegar) is readily metabolized in the liver via the tricarboxylic acid (TCA) cycle. Such volatile acids generally do not cause an elevated AG.

The traditional method for calculating AG employs a simplified formula: AG = [Na+] – ([Cl] + [HCO₃]) (24), with a normal reference range of 8–16 mmol/L (25). This approach does not account for the influence of substances such as albumin (ALB) and phosphate in plasma, nor does it consider cations like K+, Mg2+, or Ca2+, leading to potential inaccuracies in assessing metabolic acid load. Consequently, researchers often apply AG correction based on specific requirements. A common clinical method is the ALB-corrected AG (ACAG). ACAG may offer improved utility in detecting hyperlactatemia (26). The adjusted AG served as a more sensitive indicator of ionic concentration changes, thus highlighting the importance of this correction (27–30). AG correction plays a significant role in the diagnosis, management, and prognostic evaluation of various diseases (31–33) and has been successfully applied in clinical cases to guide effective treatment (34–36). However, while ACAG is convenient for clinical application, there remains room for enhancing its sensitivity in scenarios demanding high precision—one of the key issues this study aims to address.

Another key indicator of the body’s acid–base balance is HCO₃, which plays a critical role in maintaining this equilibrium. HCO₃ directly measures the body’s alkaline reserve buffering capacity. Its primary mechanisms of action include the following: Firstly, as a major buffer in the blood, HCO₃ forms a buffer pair with carbonic acid (H₂CO₃). When acidic substances increase, H+ combines with HCO₃ to form H₂CO₃, which subsequently dissociates into CO₂ and H₂O; the CO₂ is then eliminated via respiration to maintain balance. Conversely, when alkaline substances increase, OH reacts with H₂CO₃ to generate HCO₃ and H₂O, thereby buffering the alkaline shift (37). In the kidneys, the precise reabsorption and secretion of HCO₃ by renal tubules finely regulate its plasma concentration. Furthermore, abnormalities in intestinal absorption or loss of HCO₃ can also lead to acid–base disturbances (37).

Studies have demonstrated that gastric acid secretion is significantly influenced by systemic acid–base balance, which is closely tied to blood acid load (38–40). This implies that an increased metabolic acid load may exacerbate gastric acid attack. Could PUD pathogenesis therefore be associated with acid load at the systemic level? To address this question, this retrospective case–control study analyzes the relationship between serum AG, HCO₃, and PUD, exploring the role of systemic acid–base imbalance in PUD. To minimize the confounding effects of hepatic and renal dysfunction, the study was conducted in a population with normal liver and kidney function, aiming to observe their independent associations. Additionally, to address the theoretical negative collinearity between AG and HCO₃, a dual-model strategy was employed: an AG model to specifically evaluate the effect of metabolic acid load, and an HCO₃ model to independently assess the role of alkaline reserve status. Moreover, to reduce the estimation error associated with AG for assessing metabolic acid load, we corrected AG to avoid masking any potential effects. Finally, post-hoc power analysis was conducted to quantitatively evaluate the robustness of the statistical findings.

Methods

Study design and participants

A retrospective case–control study was conducted using data from individuals who underwent comprehensive biochemical testing and gastroscopy at a tertiary hospital in Fujian Province. Data on biochemical tests and gastroscopy results were retrieved from the hospital’s health examination system for the period from January 14, 2023, to June 30, 2025. Participants were categorized into two groups based on gastroscopic findings: those diagnosed with active peptic ulcer (including gastric or duodenal ulcers with clear active-stage classification A1 or A2) were assigned to the case group, while those with no abnormal findings were assigned to the control group.

Ethical approval

It was approved by the Putian University Institutional Review Board (Approval No. 2024044). The requirement for informed consent was waived because this was a retrospective analysis of de-identified medical records, posed minimal risk to participants, and the research could not practicably be carried out without the waiver. All data were anonymized prior to analysis, and patient confidentiality was strictly maintained in accordance with national regulations on human subjects research.

Inclusion and exclusion criteria were as follows

  • (1) Case group inclusion: Endoscopically diagnosed peptic ulcer (gastric or duodenal ulcer) with documented active stage (A1 or A2).

  • (2) Control group inclusion: The endoscopic findings comprised solely of a single diagnosis of gastric mucosal status (atrophic or non-atrophic) and did not include any abnormal lesions (such as erosions, acute inflammation, leukoplakia, etc.).

  • (3) Common exclusion criteria (both groups):

  1. Incomplete clinical data.

  2. Endoscopic findings indicating esophageal/gastric varices, hiatal hernia, bleeding, esophagitis, or any malignancy.

  3. Age < 18 or ≥ 80 years.

  4. Abnormal liver or kidney function, defined as alanine aminotransferase (ALT) > 40 U/L, aspartate aminotransferase (AST) > 40 U/L (upper limits of normal), or creatinine (Cr) > 73 μmol/L (upper limit of normal by enzymatic assay).

  5. Duplicate examination records—only the first record was retained.

Sample size

As an exploratory analysis based on existing data, no prior sample size calculation was performed. A total of 64 cases and 541 controls were included, yielding a final sample size of 605 participants. Post-hoc power analysis was conducted to evaluate the detectability of the observed effects given the available sample size.

Variable definitions

Outcome Variable: PUD status (case = 1, control = 0). Primary Exposure A: Corrected AG (AGcorr, mmol/L), derived from venous serum biochemical measurements, serving as a reliable indicator of metabolic acid load. Primary Exposure B: HCO₃ (mmol/L), obtained from venous serum biochemical testing. Adjustment Variables: Sex (male/female), age (years, continuous), and serum sodium (Na+, mmol/L) to account for potential confounding related to sex, age, and fluid volume status.

Model definitions

To mitigate potential collinearity between AGcorr and HCO₃—both physiological and statistical—and to elucidate their distinct pathophysiological roles, three complementary multivariable logistic regression models were constructed: (1) Model A (Metabolic Acid Load Model): Included AGcorr as the key exposure to specifically assess the independent association between metabolic acid load (reflecting accumulation of unmeasured anions) and PUD risk. (2) Model B (Alkaline Reserve Model): Included HCO₃ as the key exposure to independently evaluate the effect of alkaline reserve status (reflecting the body’s buffering capacity against acid load) on PUD. (3) Model C (uncorrected AG Model): Included uncorrected AG as the key exposure. (4) Model D (ACAG Model): Included ACAG as the key exposure. All models were adjusted for sex, age, and serum sodium.

A novel correction of the AG

The traditional formula for calculating AG, without considering ALB and other electrolytes, is: AG = [UA] − [UC] = [Na+] − ([Cl] + [HCO₃]). This formula has significant limitations as it disregards contributions from other measured cations (e.g., Ca2+, K+, Mg2+), anions (e.g., P), and ALB. Accordingly, we developed a comprehensive corrected AG formula that incorporates all the aforementioned indicators. Based on the principle of electrical neutrality: Total Positive Charge = Total Negative Charge. If “[]” represents the total charge contribution of the respective electrolyte, [Na+] + [K+] + [Ca2+] + [Mg2+] + [UC] = [Cl] + [HCO₃] + [ALB] + [P] + [UA]. Since [AG] = [Na+] − ([Cl] + [HCO₃]), therefore [AG] + [K+] + [Ca2+] + [Mg2+] + [UC] = [ALB] + [P] + [UA]; therefore [UA] − [UC] = [AG] + [K+] + [Ca2+] + [Mg2+] − [P] − [ALB], therefore AGcorr mmol/L = (AG + ΔK+ + ΔCa2+ + ΔMg2+ − ΔP − ΔALB) mmol/L, and ACAG = (AG − ΔALB) mmol/L. Among them, ΔALB = (measured ALB − normal ALB) × 0.25 (0.25 is the average charge correction factor for serum ALB (g/L), normal ALB ≈ 40 g/L), ΔK+ = (measured K − normal K) × 1 (1 is the charge coefficient for K+, normal K (mmol/L) ≈ 4 mmol/L), ΔCa2+ = (measured Ca − normal Ca) × 2 (2 is the charge coefficient for Ca2+, normal Ca (mmol/L) ≈ 2.4 mmol/L), ΔMg2+ = (measured Mg − normal Mg) × 2 (2 is the charge coefficient for Mg2+, normal Mg (mmol/L) ≈ 0.85 mmol/L), ΔP = (measured P − normal P) × 1.8 (1.8 is the average charge correction factor for serum phosphate ions, normal P (mmol/L) ≈ 1 mmol/L). Using the AGcorr instead of AG eliminates the falsely normal AG level caused by low ALB levels, thereby improving the detection of occult high-AG acidosis. AGcorr also isolates interference from abnormalities in K+, Mg2+, or P, more reliably reflecting the accumulation of metabolic acids (e.g., lactate, ketones).

At the physiological pH of human serum, inorganic phosphorus exists primarily as a mixture of HPO₄2− and H₂PO₄1−. The ratio of the two is approximately 4:1 at the physiological pH of 7.4, as derived from the Henderson-Hasselbalch equation. Consequently, according to classical theory based on physicochemical principles, the weighted average charge correction factor is calculated as: (0.8 × 2) + (0.2 × 1) = 1.8. The ALB molecule, composed of 585 amino acids and rich in cysteine residues, adopts a negatively charged globular protein structure. Based on the modulation and refinement of the molecular charge of ALB, the charge-weighted correction factor was established, becoming an important parameter in hematological physiology research. The classical charge-weighted correction factor for ALB is 2.5. This coefficient is widely applied in hematology, pharmacology, and clinical therapeutics for the accurate assessment and rational utilization of ALB’s functions (41–44).

Statistical analysis

A database was established using Excel software, and statistical analyzes were conducted mainly with SPSS version 26.0. All data points were retained in the analysis unless an unambiguous cause for abnormality was identified (e.g., batch effects, sample contamination, or instrument malfunctions). A p value less than 0.05 was deemed statistically significant. Categorical data were summarized using frequencies or composition ratios, whereas continuous data were represented by the mean ± standard deviation ( ± s) or median (interquartile range, IQR), as appropriate. A Chi-square test was performed for sex. Binary logistic regression was performed to identify influencing factors. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the univariate association between each independent variable and PUD. Collinearity was assessed using linear regression and quantified by the variance inflation factor (VIF). The sample size was estimated a priori, and the statistical power was evaluated post hoc using G-Power 3.1. Data were visualized using bar and box plots. A case–control matching was performed using R software (version 4.2.2) to match participants on sex and age, adjusting the case and control groups for sensitivity analysis.

Results

Descriptive statistics

The final analysis included 605 participants, comprising 64 patients with endoscopically confirmed PUD and 541 endoscopically confirmed non-PUD healthy controls, aged between 18 and 80 years. The control group consisted of 541 individuals (83 males, 458 females), while the case group included 64 patients (19 males, 45 females). Baseline characteristics of the study population are summarized in Table 1. The differences of age, sex, Na, HCO₃, AG, AGcorr, and ACAG between controls and cases was compared. Results showed significant differences in AGcorr, ACAG, AG, Age and sex between the two groups (p < 0.05 or p < 0.001). There was no significant difference in Na and HCO₃ between the two groups. See Figure 1 and Table 1 for details.

Table 1.

Differences in indicators between two groups ( ± s) or [median (IQR)].

Variables Overall data Control group (n = 541) Case group (n = 64) Z/χ 2 /t P
Age (years) 45 (36, 54) 44 (35, 54) 52 (44, 58) −4.354a <0.001
Sex (male %) 16.86 15.34 29.69 8.402b 0.004
Na (mmol/L) 139.70 (138.30, 141.00) 139.60 (138.30, 140.95) 139.92 ± 2.07 −1.616a 0.106
AGcorr (mmol/L) 8.61 (7.20, 10.34) 8.53 (7.08, 10.20) 9.80 ± 2.21 −3.545a <0.001
HCO₃ (mmol/L) 25.13 ± 2.56 25.17 ± 2.59 24.78 ± 2.32 1.158c 0.247
AG (mmol/L) 10.50 ± 2.58 10.42 ± 2.61 11.15 ± 2.16 −2.146c 0.032
ACAG (mmol/L) 9.03 (7.40, 10.68) 8.85 (7.13, 10.48) 10.02 ± 2.19 −3.300a 0.001

“a” represents the Z value of the Mann–Whitney U test. “b” represents the χ2 value of the Pearson chi-square test. “t” represents the t-value of the t-test. AG, Anion gap; AGcorr, Corrected AG; ACAG, Albumin corrected AG.

Figure 1.

Box plot comparing Z-scores for serological markers ACAG, AG, HCO3, and AGcorr between control and case groups. Blue represents control, red represents case. Results showed significant differences in AGcorr, ACAG, and AG between the two groups.

Boxplots of standardized values of HCO3 and AGcorr in two groups.

Univariate analysis

Univariate binary logistic regression analysis revealed significant associations of Sex, Age, AGcorr, AG, and ACAG with PUD (p < 0.05), but not with HCO₃ or Na. Details are provided in Table 2, and variable assignments are summarized in Table 3.

Table 2.

Univariable binary logistic regression of factors associated with PUD.

Variables B SE Wald χ2 P OR 95%CI
Sex 0.846 0.298 8.030 0.005 2.330 1.298–4.182
Age 0.050 0.012 17.503 <0.001 1.051 1.027–1.076
Na 0.100 0.068 2.136 0.144 1.105 0.967–1.263
AGcorr 0.170 0.052 10.899 0.001 1.185 1.072–1.311
HCO₃ −0.060 0.052 1.341 0.247 0.942 0.851–1.042
AG 0.107 0.050 4.546 0.033 1.113 1.009–1.229
ACAG 0.147 0.050 8.462 0.004 1.158 1.049–1.278

Table 3.

Variable assignment.

Category Variable name Assignment/values
Dependent variable Group 0 = Control, 1 = PUD
Independent variables Sex 0 = Female, 1 = Male
Age Original values
Serological markers

Multivariate analysis

Multivariate binary logistic regression analysis was conducted in three models. Each model was distinguished by its key variable: Model A: AGcorr; Model B: HCO₃; Model C: uncorrected AG; Model D: ACAG. All models adjusted for sex, age, and sodium (Na). The results identified AGcorr (B = 0.155, p = 0.004) as a positive correlation factor for PUD. HCO₃ (B = −0.112, p = 0.043) acted as a negative correlation factor. The uncorrected AG made a significant contribution (B = 0.104, p = 0.049), while the overall model showed a poor fit with the Hosmer-Lemeshow test (H-L test χ2 = 17.895, p = 0.022). Model D was also significantly correlated (p < 0.05) but showed poor fit (H-L test χ2 = 15.796, p = 0.045). Prior to performing multivariate logistic regression, collinearity diagnostics were conducted for all independent variables in the models. VIF analysis demonstrated that all variables in the models had values ranging from 1.0 to 1.2. All values were well below the threshold of 5, indicating the absence of severe multicollinearity in the models. Details are shown in Table 4; variable coding is provided in Table 3.

Table 4.

Multivariate binary logistic regression for factors associated with PUD.

Models Variable B SE Wald χ2 P OR 95%CI
Model Aa Sex 0.896 0.310 8.354 0.004 2.449 1.334–4.495
Age 0.050 0.013 16.040 <0.001 1.051 1.026–1.078
Na −0.014 0.074 0.035 0.851 0.986 0.853–1.140
AGcorr 0.155 0.054 8.171 0.004 1.167 1.050–1.298
Constant −4.218 10.129 0.173 0.677 0.015
Model Bb Sex 0.960 0.309 9.651 0.002 2.612 1.425–4.788
Age 0.053 0.013 17.936 <0.001 1.055 1.029–1.081
Na 0.047 0.073 0.414 0.520 1.048 0.909–1.209
HCO₃ −0.112 0.055 4.113 0.043 0.894 0.802–0.996
Constant −8.633 9.915 0.758 0.384 0.000
Model Cc Sex 0.052 0.012 17.172 <0.001 1.053 1.028–1.079
Age 0.913 0.308 8.785 0.003 2.492 1.362–4.558
Na −0.004 0.073 0.003 0.958 0.996 0.863–1.150
AG 0.104 0.053 3.863 0.049 1.110 1.000–1.232
Constant −5.391 10.032 0.289 0.591 0.005
Model Dd Sex 0.934 0.309 9.117 0.003 2.544 1.388–4.664
Age 0.050 0.012 16.283 <0.001 1.052 1.026–1.078
Na −0.009 0.073 0.016 0.900 0.991 0.858–1.144
ACAG 0.138 0.053 6.856 0.009 1.148 1.035–1.273
Constant −4.773 10.098 0.223 0.636 0.008

“a” represents H-L test χ2 = 9.853, p = 0.276; Nagelkerke R2 = 0.115. “b” represents: H-L test 10.910, p = 0.207; Nagelkerke R2 = 0.102. “c” represents: H-L test χ2 = 17.895, P = 0.022; Nagelkerke R2 = 0.101. “d” represents: H-L test χ2 = 15.796, P = 0.045; Nagelkerke R2 = 0.111.

Post hoc power analysis

Model A

Based on a total sample size of 605 and the observed effect (OR = 1.167), a post hoc power analysis indicated a statistical power of 89%. Sensitivity analysis revealed that the study conclusions were relatively sensitive to changes in sample size: when the sample size was reduced to 400, the power decreased to 75%, falling below the conventionally accepted threshold; when the sample size was increased to 800, the power rose to 95%. Considering the prior sensitivity analysis on effect size, this study possesses sufficient power to detect the observed effect but exhibits limited capability to withstand fluctuations in sample size or to detect weaker effects. See Table 5 for details.

Table 5.

Post hoc power and sensitivity analysis results for models.

Models (target variable) Scenario OR Power N Parameters
Model A (AGcorr) Baseline 1.167 0.89 605 R2 other X = 0.033, SD = 2.49
Sensitivity (OR)
Conservative 1.05 0.23 605 Identical to baseline
Mild conservative 1.10 0.55 605 Identical to baseline
Optimistic 1.20 0.96 605 Identical to baseline
Highly optimistic 1.30 0.99 605 Identical to baseline
Sensitivity (N)
Insufficient N 1.167 0.75 400 Identical to baseline
Sufficient N 1.167 0.95 800 Identical to baseline
Model B (HCO₃) Baseline 0.894 0.68 605 R2 other X = 0.058, SD = 2.56
Sensitivity (OR)
Highly optimistic 0.805 0.99 605 Identical to baseline
Optimistic 0.850 0.93 605 Identical to baseline
Mild conservative 0.983 0.09 605 Identical to baseline
Conservative 1.028 0.13 605 Identical to baseline
Sensitivity (N)
Insufficient N 0.894 0.53 400 Identical to baseline
Minimally sufficient 0.894 0.80 835 Identical to baseline
Sufficient N 0.894 0.86 1,000 Identical to baseline
Model C (AG) Baseline 1.110 0.64 605 R2 other X = 0.028, SD = 2.58
Model D (ACAG) Baseline 1.148 0.84 605 R2 other X = 0.027, SD = 2.55

Model B

Although the association between HCO₃ and the outcome reached statistical significance (OR = 0.894, 95% CI: 0.802–0.996, p < 0.05), a post hoc power analysis showed a baseline power of only 0.65. The sensitivity analysis revealed substantial uncertainty: if the true effect was near the lower confidence limit (OR = 0.805), the statistical power would be as high as 0.99; conversely, if the true effect was near the upper confidence limit (OR = 1.028), the power would be only 0.13. This indicates that the current estimate of the effect size is highly imprecise. Using G*Power analysis, with all other parameters held constant, approximately 835 participants would be required to reliably detect an effect size of OR = 0.894 with 80% power. See Table 5 for details.

Model C

The post hoc power analysis revealed that Model C had a power of only 0.64. Although the uncorrected AG showed a statistically significant association with PUD, its low post hoc power (0.64) and suboptimal model fit (H-L test p < 0.05) suggest that this finding lacks robustness and has limited statistical power. See Table 5 for details.

Model D

The post hoc power analysis revealed that Model D had a power of 0.84. ACAG showed a statistically significant association with PUD (p < 0.05), a post hoc power of 0.84, and suboptimal model fit (H-L test p < 0.05). It suggests that Model D is an “efficient but imprecise” detector. See Table 5 for details.

Sensitivity analysis

Binary logistic regression analysis with adjusted control group

To assess the robustness of our findings, we performed a sensitivity analysis by altering the definition of the control group. We replaced the original controls (“Endoscopically confirmed, healthy individuals without PUD”) with a more broadly defined cohort (“Endoscopically confirmed, relatively healthy individuals without PUD”). The inclusion criteria for controls were expanded from the primary model’s requirement of a single diagnosis related to gastric mucosal status to allowing multiple benign endoscopic diagnoses, including conditions such as erosions, mucosal inflammation, and leukoplakia. The exclusion criteria remained consistent with the primary model.

The AGcorr level was 8.53 (7.08–10.20) in the primary model’s control group (n = 541) and 8.93 ± 2.52 in the sensitivity analysis’ adjusted control group (n = 1915). The case group (n = 64 active PUD patients) remained identical to the primary model.

The results demonstrated that the association between AGcorr and PUD remained statistically significant in the model with the adjusted control group (OR = 1.138, 95% CI: 1.029–1.259, p = 0.012). Although the inclusion of a more heterogeneous control group introduced potential confounders that could reduce statistical power, the post-hoc power of this model was 0.81, still exceeding conventionally accepted thresholds, and the model fit was good (H-L test χ2 = 7.764, p = 0.457). This confirms that our core conclusion—metabolic acid load is a positive correlation factor for PUD—is robust to changes in the control group definition. See Table 6 for details.

Table 6.

Sensitivity analysis for model A with an adjusted control group.

Model A Control AGcorr level (mmol/L) n (case/control) AGcorr OR (95% CI) P Power H-L P
Primary Healthy 8.53 (7.08, 10.20) 64/541 1.167 (1.050–1.298) 0.004 0.89 0.276
Sensitivity Relatively healthy 8.93 ± 2.52 64/1915 1.138 (1.029–1.259) 0.012 0.81 0.457

Binary logistic regression analysis with case–control matching

Case–control matching was performed on sex and age to eliminate their effects on PUD. After matching, 289 cases were obtained, comprising 52 subjects in the case group (44 females, 8 males) and 237 subjects in the control group (219 females, 18 males). Binary logistic regression results indicated that sex, age, and Na did not have a significant effect on PUD (B = 0.150, p > 0.05), while AGcorr showed a significant effect on PUD (p < 0.05). Following the matching for sex and age, the explanatory power of the model was limited due to the elimination of a large number of control cases (Nagelkerke R2 = 0.049). However, AGcorr still demonstrated stable significance, which is sufficient as a sensitivity analysis to support the robustness of the original model. See Table 7 for details.

Table 7.

Sensitivity analysis with case–control matching on sex and age.

Variable B SE Wald χ2 P OR 95%CI
Sex 0.882 0.466 3.587 0.058 2.417 0.970–6.032
Age 0.009 0.017 0.304 0.581 1.009 0.976–1.044
Na −0.045 0.089 0.259 0.611 0.956 0.804–1.137
AGcorr 0.150 0.064 5.402 0.020 1.161 1.024–1.317
Constant 2.863 12.025 0.057 0.812 17.508

n (case) = 52, n (control) = 237. H-L test χ2 = 11.453, p = 0.177; Nagelkerke R2 = 0.049.

Discussion

Principal findings

First, this study developed a novel formula for calculating the AG. Second, this study employed two independent multivariable logistic regression models to investigate the association between acid–base balance markers—AGcorr and HCO₃—and PUD in a population excluding individuals with abnormal liver or kidney function. On one hand, AGcorr demonstrated a robust and positive association with PUD; on the other hand, HCO₃ suggested a potential negative association.

Metabolic acid load and PUD

It is well established that gastric acid is the most critical aggressive factor in the pathogenesis of PUD. But is there a connection between gastric acid and systemic acid–base balance? In fact, existing studies have already revealed physiological mechanisms linking the two. It is possible that an important fact has long been overlooked: gastric acid secretion may serve as an important buffering pathway during episodes of metabolic acidosis in the body. Gastric acid secretion is primarily regulated by H+/K+-ATPase activity in gastric parietal cells (45, 46). The gastric H+, K+, -ATPase derives energy from the hydrolysis of ATP to transport H+ ions from the parietal cells of the gastric mucosa into the stomach in exchange for K+ ions. This is the mechanism of gastric acid secretion (47). Gastric acid secretion may be influenced by serum acid loading status. Electrolytes in the blood and across intracellular and extracellular compartments are exchanged and regulated through complex mechanisms (48). Excessive blood acid load may lead to increased gastric acid secretion, thereby exacerbating damage to the gastric mucosa. Studies have indicated that systemic acid–base imbalances modulate gastric acid secretion by influencing electrolyte transport and altering pH levels both intracellularly and extracellularly (49). Studies have shown that chronic metabolic acidosis in patients with chronic kidney disease (CKD) is associated with gastrointestinal mucosal damage and an increased risk of ulcers and bleeding (16, 17). In addition, a study of experimental acidotic mice revealed a significant increase in the transcript level of Atp4A and its protein expression in the stomachs of acidosis mice compared with control mice (50). The Atp4A gene encodes a key subunit of the proton pump responsible for gastric acid secretion. Taken together, the above discussion supports that an increased systemic acid load may elevate gastric acid secretion, which is the most significant aggressive factor in PUD. Therefore, there is reason to believe that the increase in metabolic acid load leads to PUD, rather than PUD causing the increase in metabolic acid load. Moreover, there is currently no evidence to suggest that peptic ulcer disease universally leads to an increased metabolic acid load.

The results of this study provide strong evidence from Model A that a statistically significant and reliable positive association exists between AGcorr and PUD (OR = 1.167, p < 0.05), supporting the inference that it acts as a risk factor for PUD. A chronic metabolic acidosis state may represent an important pathogenic mechanism of PUD. Post-hoc power analysis based on the observed effect size and current sample size (N = 605) indicated high statistical power (Power = 89%) to detect this association, supporting the robustness of the result. Sensitivity analysis of the OR suggested limitations in detecting weak effects; future research should focus on precisely quantifying the strength of this effect and further exploring its underlying mechanisms and practical implications. Sensitivity analysis with an adjusted control group showed that even under more stringent conditions—by including more potential confounders (which generally dilutes effect estimates)—the association between AGcorr and PUD remained statistically significant, with a statistical power of 0.81 for this comparison. Sensitivity analysis of case–control matching on sex and age also demonstrated the significant effect of AGcorr on PUD. This indicates that the effect of AGcorr on PUD is not coincidental and that the finding is robust. Such robustness substantially enhances the internal validity and scientific rigor of our conclusion and increases its potential relevance for clinical application.

From a pathophysiological perspective, elevated AG often suggests the accumulation of unmeasured anions (e.g., lactate, ketone bodies, uremic organic acids). After controlling for potential confounding from liver and kidney function, this study established that corrected AG can serve as a robust risk marker for PUD—i.e., the accumulation of metabolic acid load increases the risk of PUD. By excluding the influence of liver and kidney function, our findings imply that metabolic accumulation may represent a more direct mechanism in PUD pathogenesis. These results support the hypothesis that PUD may involve an underrecognized state of high metabolic acid load, and that this persistent metabolic stress could be an overlooked mechanism driving disease progression. In the context of PUD, AGcorr is more likely to be a proactive risk driver. Its robust association strongly suggests that the metabolic acid load represented by AG may itself be a previously overlooked pathological mechanism directly involved in the development of PUD. The acid-secreting function of the gastric mucosa may serve as an important pathway for systemic acid–base balance regulation (analogous to renal tubular acid secretion). A persistent systemic acid load may upregulate gastric acid secretion at the systemic level, thereby increasing aggressive factors acting on the gastric mucosa and contributing to the pathogenesis of PUD.

Therefore, the broader significance of this study lies in proposing a new perspective on PUD pathogenesis—an “metabolic acid attack” pathway that transcends the conventional intragastric microenvironment. We reveal that within the complex pathogenic network of PUD, in addition to local aggressive factors such as H. pylori and NSAIDs, a systemic metabolism-derived “metabolic acid attack” pathway may be equally important. Naturally, this “metabolic acid attack” hypothesis requires final confirmation through prospective studies, including direct comparisons and interaction analysis with traditional risk factors. Nonetheless, this study undoubtedly introduces a new metabolic dimension to understanding and addressing PUD—a classic condition.

Methodological innovation: the value of the fully-corrected AG formula in PUD assessment

Another major advance of this study lies in its methodological breakthrough. Building upon the simplified formula AG = [Na+] – ([Cl] + [HCO₃]), we have developed and validated a comprehensive AG correction formula. Unlike traditional approaches that adjust only for ALB or focus on individual electrolytes, our formula systematically integrates potassium (K+), magnesium (Mg2+), calcium (Ca2+), phosphorus (P), and ALB into the AG calculation and has applied it in our models. The inclusion of these parameters is grounded in solid physiological and biochemical rationale. The traditional AG ignores the influence of these factors, potentially leading to significant discrepancies between the estimated AG and the true metabolic acid load. Consequently, our new model aims to integrate these key parameters to construct an assessment tool that more accurately approximates the “true” metabolic acid load in vivo. The results of this study provide clinically useful reference values: the AGcorr levels were 8.53 (7.08–10.20) in the Model A control group (541 adults) and 8.93 ± 2.52 in the adjusted control group (1915 adults) of the sensitivity analysis model.

The comparison between Model A and Model C underscores the necessity of AG correction. The results from Model C (uncorrected AG) provide crucial counter-evidence highlighting the importance of comprehensive correction. Although the uncorrected AG also showed statistical significance, its poor model fit (H-L test p < 0.05) and low statistical power (0.64) collectively indicate that the uncorrected AG is a crude and unreliable risk indicator. The disadvantages of Model C, when contrasted with the robust and efficient Model A, highlight the exceptional value of the fully-corrected AG—representing a transition from crude to precise, and from inefficient to efficient. This comparison strongly demonstrates that comprehensive AG correction is not an optional refinement but a critical step in transforming AG from an unstable signal into a robust biomarker. It removes the “noise” introduced by variations in other electrolytes and proteins, allowing us to capture the true effect of the metabolic acid attack on PUD more clearly and reliably.

The results from Model D (ACAG Model) indicate that eliminating ALB interference is a necessary step to unlock AG’s predictive potential, resulting in a leap in its statistical power. However, its suboptimal model fit also exposes limitations, suggesting that while ALB correction is necessary, it is not sufficient. The final Model A demonstrates that only through comprehensive correction, which simultaneously accounts for electrolytes like potassium, magnesium, calcium, and phosphorus that collectively form the acid–base balance network, can an ideal biomarker be obtained—one that is both sensitive and well-calibrated.

There is currently no universally accepted formula for AG correction, and numerous studies have tailored their correction approaches to their specific research objectives, achieving robust results (27–30). This study developed a novel fully-corrected AG formula suitable for assessing metabolic acid load (as opposed to alkali loss) and demonstrated its superiority over traditional AG and ACAG in PUD-related mechanistic investigations, showing robust sensitivity. Our findings confirm that the fully-corrected AG index demonstrates robust sensitivity in detecting disturbances associated with PUD. This discovery strongly suggests a possible widespread prevalence among PUD patients of a subtle yet persistent “subclinical metabolic acidosis” state caused by a “high metabolic acid load”—a condition previously masked by the insufficient sensitivity of detection tools. The nature of this state may stem from a chronic imbalance between metabolic acid production and clearance, potentially due to complex dietary patterns or specific metabolic phenotypes. In terms of clinical translation, this work theoretically opens new perspectives for understanding the systemic metabolic etiology of PUD, revealing an metabolic acid attack pathway independent of traditional local factors. In the future, this fully-corrected AG formula holds promise as a sensitive biological marker to be integrated into PUD risk prediction models.

HCO₃ and PUD

Based on physiological principles, the body’s alkaline reserve can counteract acidic metabolites. Therefore, if metabolic acid load is a risk factor for PUD, then the alkaline buffer system that counteracts it would be a protective factor. Our findings suggest a potential negative correlation between HCO₃ and PUD, supporting the inference that it acts as a protective factor. For Model B (the HCO₃ model), the current study had only 65% power to detect the observed effect (OR = 0.894). The present sample size is insufficient to precisely estimate an effect close to the null boundary. The low baseline power (0.65) and extreme sensitivity analysis results indicate that we cannot reliably distinguish whether HCO₃ has a substantial protective effect (OR = 0.802) or is nearly ineffective (OR = 0.996). Although the association was statistically significant, this finding may lack robustness, and the true effect is likely weaker than the point estimate suggests. Sample size sensitivity analysis provides clear guidance: the current sample size of 605 is clearly inadequate for verifying the HCO₃ effect (power = 0.65). It would need to be increased to 835 subjects to reach the acceptable power threshold (0.80), or to 1,000 subjects to achieve robust statistical power (0.86).

Alignment with and extension of existing theoretical consensus

Traditionally, PUD and stress ulcers (SU) have been regarded as having distinct pathogenic mechanisms, and their etiologies have rarely been linked. However, this study may challenge this conventional separation, as an elevated systemic acid load could represent a shared underlying mechanism for both conditions. A substantial amount of evidence from previous literature readily supports the association between acidosis and SU. Jiang Lanting et al. reported that SU are associated with elevated lactic acid levels (51), while Li Bing et al. found that metabolic acidosis is one of the independent risk factors for severe craniocerebral injury complicated by SU (52). Kivilaakso suggested that metabolic acidosis characterized by “low HCO₃” can reduce HCO₃ supply to the mucosa, thereby increasing its susceptibility to ulcers (53). Other scholars have reported that metabolic acidosis is a significant risk factor for acute spinal cord injury and SU (54). A patient with SU induced by thyrotoxicosis was complicated by high anion-gap acidosis (55). Furthermore, multiple studies globally have documented that patients with diabetic ketoacidosis (DKA) frequently develop SU or experience gastrointestinal bleeding. Hao et al. (56), Uhlenhopp et al. (57), Badipatla et al. (58) propose that lactate levels can be used as a predictive marker for gastrointestinal bleeding (58). Therefore, we can speculate that acidosis, particularly metabolic lactic acidosis, may be a fundamental mechanism underlying the development of SU. The correlation between acute stress ulcers and metabolic acid load may underpin the pathogenesis of PUD.

Strengths and limitations

The primary strength of this study lies in our proactive exclusion of individuals with abnormal liver or kidney function, which effectively controlled for these key confounding factors. Additionally, by adjusting for the influences of sex, age, and fluid volume differences, we were able to more clearly reveal the relationship between PUD itself and acid–base balance. Furthermore, moving beyond mere reporting of p-values, we employed post-hoc power and sensitivity analysis to provide quantitative support for the robustness of our conclusions, adhering to a more transparent and responsible reporting standard.

This study has several limitations. Binary logistic regression results from Model A indicated that both sex and age had significant effects on PUD. To eliminate their influence on PUD, we performed case–control matching for sex and age. The subsequent binary logistic regression analysis showed that AGcorr remained a significant factor for PUD, confirming that its effect is independent of sex and age. Due to the inherent nature of the retrospective design, we were unable to systematically obtain and adjust for all participants’ H. pylori infection status and NSAIDs use, both of which are well-established risk factors for PUD. This may lead to residual confounding and represents an important consideration when interpreting our results. In addition, regarding the analysis of HCO₃, it is possible that its effect is inherently extremely weak and unstable, or that our sample size was insufficient. Although this study found that it has a potential protective effect on PUD, further research with a larger sample size is needed to clarify its exact role.

Summary

After adjusting for sex, age, and Na, AGcorr remained an independent risk factor for PUD in individuals with normal liver and kidney function. Metabolic non-volatile acid attack may be an important pathogenic mechanism in PUD. Through our original comprehensive correction formula, we transformed AG into a highly sensitive indicator, revealing for the first time a prevalent “subclinical metabolic acidosis” state among PUD patients—a finding that warrants substantial attention from clinicians. The fully-corrected AG demonstrated significantly superior model fit and statistical power compared to the uncorrected AG and ACAG, establishing it as a robust and reliable biomarker. We recommend its integration into clinical PUD risk assessment and disease management pathways to facilitate a shift toward earlier and more proactive prevention and treatment strategies. Furthermore, we also discovered that the HCO₃ might be a potential protective factor, but its clinical significance still needs to be further confirmed. From a nutritional perspective, correcting the acid–base imbalance caused by non-volatile acids and reducing AGcorr could be a key mitigating strategy for preventing and treating PUD. Increasing the alkaline reserve may also be a potential therapeutic approach. These findings require further validation in broader populations to better control for confounding factors and enhance their generalizability.

Funding Statement

The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Startup Fund for Advanced Talents of Putian University [No. 2021076]. The funding source had no involvement in study design, data collection, analysis, interpretation, or the decision to submit the article for publication. Principal Investigator: Xian-Ping Lin.

Footnotes

Edited by: Xiaolong Ji, Zhengzhou University of Light Industry, China

Reviewed by: Rong Wang, The Affiliated People’s Hospital of Fujian University of Traditional Chinese Medicine, China

Junkai Su, Zhangzhou Zhengxing Hospital, China

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by the Putian University Institutional Review Board (Approval No. 2024044). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants’ legal guardians/next of kin because this was a retrospective analysis of de-identified medical records. All data were anonymized prior to analysis, and patient confidentiality was strictly maintained in accordance with national regulations on human subjects research.

Author contributions

X-PL: Funding acquisition, Writing – review & editing, Conceptualization, Software, Investigation, Writing – original draft, Resources, Project administration, Validation, Formal analysis, Data curation, Supervision, Visualization, Methodology. S-XL: Writing – review & editing, Resources, Data curation.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that Generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1.Cai S, García Rodríguez LA, Massó-González EL, Hernández-Díaz S. Uncomplicated peptic ulcer in the UK: trends from 1997 to 2005. Aliment Pharmacol Ther. (2009) 30:1039–48. doi: 10.1111/j.1365-2036.2009.04131.x, [DOI] [PubMed] [Google Scholar]
  • 2.Yang H, Zhang M, Li H, Huang Z, Sun Y, Li W, et al. Prevalence of common upper gastrointestinal diseases in Chinese adults aged 18-64 years. Sci Bull (Beijing). (2024) 69:3889–98. doi: 10.1016/j.scib.2024.07.048, [DOI] [PubMed] [Google Scholar]
  • 3.Marques MS, Costa AC, Osório H, Pinto ML, Relvas S, Dinis-Ribeiro M, et al. Helicobacter pylori PqqE is a new virulence factor that cleaves junctional adhesion molecule a and disrupts gastric epithelial integrity. Gut Microbes. (2021) 13:1–21. doi: 10.1080/19490976.2021.1921928, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Sanaei MJ, Shirzad H, Soltani A, Abdollahpour-Alitappeh M, Shafigh MH, Rahimian G, et al. Up-regulated CCL18, CCL28 and CXCL13 expression is associated with the risk of gastritis and peptic ulcer disease in Helicobacter Pylori infection. Am J Med Sci. (2021) 361:43–54. doi: 10.1016/j.amjms.2020.07.030, [DOI] [PubMed] [Google Scholar]
  • 5.Cho J, Prashar A, Jones NL, Moss SF. Helicobacter pylori infection. Gastroenterol Clin N Am. (2021) 50:261–82. doi: 10.1016/j.gtc.2021.02.001, [DOI] [PubMed] [Google Scholar]
  • 6.Morales-Espinosa R, Delgado G, Serrano LR, Castillo E, Santiago CA, Hernández-Castro R, et al. High expression of Helicobacter pylori VapD in both the intracellular environment and biopsies from gastric patients with severity. PLoS One. (2020) 15:e0230220. doi: 10.1371/journal.pone.0230220, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ko KA, Lee DK. Nonsteroidal anti-inflammatory drug-induced peptic ulcer disease. Korean J Helicobacter Up Gastrointest Res. (2025) 25:34–41. doi: 10.7704/kjhugr.2025.0004, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Cañamares-Orbís P, Lanas Arbeloa Á. New trends and advances in non-variceal gastrointestinal bleeding-series II. J Clin Med. (2021) 10:3045. doi: 10.3390/jcm10143045, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Wu Y, Murray GK, Byrne EM, Sidorenko J, Visscher PM, Wray NR. GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal disorders and depression. Nat Commun. (2021) 12:1146. doi: 10.1038/s41467-021-21280-7, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Fagundes FL, Pereira QC, Zarricueta ML, Dos Santos RC. Malvidin protects against and repairs peptic ulcers in mice by alleviating oxidative stress and inflammation. Nutrients. (2021) 13:3312. doi: 10.3390/nu13103312, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Tejada-Arranz A, De Reuse H. Riboregulation in the major gastric pathogen Helicobacter pylori. Front Microbiol. (2021) 12:712804. doi: 10.3389/fmicb.2021.712804, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Shahini Shams Abadi M, Ashrafi-Dehkordi K, Ahmadi R, Rahimian G, Mirzaei Y, Fereidani R, et al. Frequency of virulence-associated genotypes of Helicobacter pylori and their correlation with clinical outcome and histological parameters in infected patients. Heliyon. (2021) 7:e07610. doi: 10.1016/j.heliyon.2021.e07610, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Shah SC, Tepler A, Chung CP, Suarez G, Peek RM, Jr, Hung A, et al. Host genetic determinants associated with Helicobacter pylori eradication treatment failure: a systematic review and meta-analysis. Gastroenterology. (2021) 161:1443–59. doi: 10.1053/j.gastro.2021.07.043, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Waldum HL, Kleveland PM, Sørdal ØF. Helicobacter pylori and gastric acid: an intimate and reciprocal relationship. Ther Adv Gastroenterol. (2016) 9:836–44. doi: 10.1177/1756283x16663395, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Zhang H, Xue Y, Zhou LY, Liu X, Suo BJ. The changes of main upper gastrointestinal diseases and Helicobacter pylori infection status in the past thirty five years. Zhonghua Nei Ke Za Zhi. (2016) 55:440–4. doi: 10.3760/cma.j.issn.0578-1426.2016.06.008, [DOI] [PubMed] [Google Scholar]
  • 16.Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, et al. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial. Lancet. (2019) 393:1417–27. doi: 10.1016/s0140-6736(18)32562-5, [DOI] [PubMed] [Google Scholar]
  • 17.Raphael KL. Metabolic acidosis in CKD: Core curriculum 2019. Am J Kidney Dis. (2019) 74:263–75. doi: 10.1053/j.ajkd.2019.01.036, [DOI] [PubMed] [Google Scholar]
  • 18.Krupp D, Shi L, Remer T. Longitudinal relationships between diet-dependent renal acid load and blood pressure development in healthy children. Kidney Int. (2014) 85:204–10. doi: 10.1038/ki.2013.331, [DOI] [PubMed] [Google Scholar]
  • 19.Gelaye A, Haidar A, Kassab C, Kazmi S, Sinha P. Severe ketoacidosis associated with Canagliflozin (Invokana): a safety concern. Case Rep Crit Care. (2016) 2016:1656182. doi: 10.1155/2016/1656182, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Artero CT. A quick reference on anion gap and strong ion gap. Vet Clin North Am Small Anim Pract. (2026) 56:19–26. doi: 10.1016/j.cvsm.2025.09.004, [DOI] [PubMed] [Google Scholar]
  • 21.Chionh CY, Tien CS, Yeon W. Diagnostic threshold and performance of anion gap in screening for high anion gap metabolic acidosis. Singapore Med J. (2024). doi: 10.4103/singaporemedj.SMJ-2023-009 [DOI] [PubMed] [Google Scholar]
  • 22.Jdiaa SS, Abu-Alfa AK. The case | severe high-anion gap metabolic acidosis. Kidney Int. (2020) 98:1625–6. doi: 10.1016/j.kint.2020.06.013, [DOI] [PubMed] [Google Scholar]
  • 23.Alexander RT, Law L, Gil-Peña H, Greenbaum LA, Santos F. Hereditary distal renal tubular acidosis In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews (®). Seattle, WA: University of Washington, Seattle copyright © 1993–2025, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved (1993) [PubMed] [Google Scholar]
  • 24.Morikawa MJ, Ganesh PR. Acid-base interpretation: a practical approach. Am Fam Physician. (2025) 111:148–55. Available online at: https://pubmed.ncbi.nlm.nih.gov/39964926/ [PubMed] [Google Scholar]
  • 25.Masevicius FD, Dubin A. Has Stewart approach improved our ability to diagnose acid-base disorders in critically ill patients? World J Crit Care Med. (2015) 4:62–70. doi: 10.5492/wjccm.v4.i1.62, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Chawla LS, Shih S, Davison D, Junker C, Seneff MG. Anion gap, anion gap corrected for albumin, base deficit and unmeasured anions in critically ill patients: implications on the assessment of metabolic acidosis and the diagnosis of hyperlactatemia. BMC Emerg Med. (2008) 8:18. doi: 10.1186/1471-227x-8-18, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Sławuta P, Glińska-Suchocka K, Cekiera A. The use of elements of the Stewart model (strong ion approach) for the diagnostics of respiratory acidosis on the basis of the calculation of a value of a modified anion gap (AGm) in brachycephalic dogs. Pol J Vet Sci. (2015) 18:217–22. doi: 10.1515/pjvs-2015-0027, [DOI] [PubMed] [Google Scholar]
  • 28.Paliwal R, Pakavakis A, Divatia JV, Kulkarni AP. Utility of Stewart's approach to diagnose missed complex Acid-Base disorders as compared to bicarbonate-anion gap-based methodology in critically ill patients: an observational study. Indian J Crit Care Med. (2022) 26:23–32. doi: 10.5005/jp-journals-10071-24077, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Long Z, Xian G, Xiang Z, Zhu X, Zhou Y, Li Z, et al. The association between albumin-corrected anion gap and in-hospital mortality in critically ill COPD patients: a multicenter retrospective study from eICU collaborative research database. J Crit Care. (2025) 91:155260. doi: 10.1016/j.jcrc.2025.155260 [DOI] [PubMed] [Google Scholar]
  • 30.Yap E, Roche-Recinos A, Goldwasser P. Predicting ionized hypocalcemia in critical care: an improved method based on the anion gap. J Appl Lab Med. (2020) 5:4–14. doi: 10.1373/jalm.2019.029314, [DOI] [PubMed] [Google Scholar]
  • 31.Jaber JF, Standley M, Reddy R. Euglycemic diabetic ketoacidosis in pregnancy: a case report and review of current literature. Case Rep Crit Care. (2019) 2019:8769714. doi: 10.1155/2019/8769714, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Alkatheeri A, Alseddeeqi E. Euglycemic diabetic ketoacidosis induced by sodium-glucose cotransporter 2 inhibitor in the setting of prolonged fasting: a case report. J Med Case Rep. (2022) 16:138. doi: 10.1186/s13256-022-03347-1, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Lee SW, Kim S, Na KY, Cha RH, Kang SW, Park CW, et al. Serum anion gap predicts all-cause mortality in patients with advanced chronic kidney disease: a retrospective analysis of a randomized controlled study. PLoS One. (2016) 11:e0156381. doi: 10.1371/journal.pone.0156381, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Fabian E, Kramer L, Siebert F, Högenauer C, Raggam RB, Wenzl H, et al. D-lactic acidosis - case report and review of the literature. Z Gastroenterol. (2017) 55:75–82. doi: 10.1055/s-0042-117647, (D-Laktat-Azidose – Fallbericht und Literaturübersicht.) [DOI] [PubMed] [Google Scholar]
  • 35.Ryu S, Oh SK, Son SH, Jeong WJ, You YH, Ham YR. Reversible acute blindness in suspected metformin-associated lactic acidosis. J Emerg Med. (2019) 57:e153–6. doi: 10.1016/j.jemermed.2019.06.047, [DOI] [PubMed] [Google Scholar]
  • 36.Dikowita DD, Kumanan T, Muhunthan K, Arulmoli J. Euglycaemic ketoacidosis in a non-diabetic primigravida following an appendicectomy. SAGE Open Med Case Rep. (2017) 5:2050313x17700743. doi: 10.1177/2050313x17700743, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Söhngen D, Balzer C, Fuchs M, Waldschmidt D. Rehabilitation of patients with acid-base and fluid balance disorders with short bowel syndrome after ileostomies. Rehabilitation (Stuttg). (2015) 54:86–91. doi: 10.1055/s-0035-1545357 (Rehabilitation von Patienten mit Störungen des Säure-Basen- und Flüssigkeitshaushaltes mit Kurzdarmsyndrom bei Ileostoma), [DOI] [PubMed] [Google Scholar]
  • 38.Feldman MJ. Edward Berk distinguished [corrected] lecture: gastric acid secretion: still relevant? Am J Gastroenterol. (2013) 108:347–52. doi: 10.1038/ajg.2012.478, [DOI] [PubMed] [Google Scholar]
  • 39.Ghosh T, Lewis DI, Axon AT, Everett SM. Review article: methods of measuring gastric acid secretion. Aliment Pharmacol Ther. (2011) 33:768–81. doi: 10.1111/j.1365-2036.2010.04573.x, [DOI] [PubMed] [Google Scholar]
  • 40.Poupin N, Calvez J, Lassale C, Chesneau C, Tomé D. Impact of the diet on net endogenous acid production and acid-base balance. Clin Nutr. (2012) 31:313–21. doi: 10.1016/j.clnu.2012.01.006, [DOI] [PubMed] [Google Scholar]
  • 41.Gao P, Min J, Zhong L, Shao M. Association between albumin corrected anion gap and all-cause mortality in critically ill patients with acute kidney injury: a retrospective study based on MIMIC-IV database. Ren Fail. (2023) 45:2282708. doi: 10.1080/0886022x.2023.2282708, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Sheng H, Lu J, Zhong L, Hu B, Sun X, Dong H. The correlation between albumin-corrected anion gap and prognosis in patients with acute myocardial infarction. ESC Heart Fail. (2024) 11:826–36. doi: 10.1002/ehf2.14639, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Aydın S, Aksakal E. Relationship between albumin-corrected anion gap and mortality in hospitalized heart failure patients. Cureus. (2023) 15:e45967. doi: 10.7759/cureus.45967, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Hu B, Zhong L, Yuan M, Min J, Ye L, Lu J, et al. Elevated albumin corrected anion gap is associated with poor in-hospital prognosis in patients with cardiac arrest: a retrospective study based on MIMIC-IV database. Front Cardiovasc Med. (2023) 10:1099003. doi: 10.3389/fcvm.2023.1099003, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Arin RM, Gorostidi A, Navarro-Imaz H, Rueda Y, Fresnedo O, Ochoa B. Adenosine: direct and indirect actions on gastric acid secretion. Front Physiol. (2017) 8:737. doi: 10.3389/fphys.2017.00737, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Goswami S. Interplay of potassium channel, gastric parietal cell and proton pump in gastrointestinal physiology, pathology and pharmacology. Minerva Gastroenterol (Torino). (2022) 68:289–305. doi: 10.23736/s2724-5985.21.02964-8, [DOI] [PubMed] [Google Scholar]
  • 47.Lee YHG, Cerf NT, Shalaby N, Montes MR, Clarke RJ. Bioinformatic study of possible acute regulation of acid secretion in the stomach. J Membr Biol. (2024) 257:79–89. doi: 10.1007/s00232-024-00310-7, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Seifter JL, Chang HY. Extracellular Acid-Base balance and ion transport between body fluid compartments. Physiology (Bethesda). (2017) 32:367–79. doi: 10.1152/physiol.00007.2017, [DOI] [PubMed] [Google Scholar]
  • 49.Seifter JL. Body fluid compartments, cell membrane ion transport, electrolyte concentrations, and Acid-Base balance. Semin Nephrol. (2019) 39:368–79. doi: 10.1016/j.semnephrol.2019.04.006, [DOI] [PubMed] [Google Scholar]
  • 50.Daher R, Ducrot N, Lefebvre T, Zineeddine S, Ausseil J, Puy H, et al. Crosstalk between acidosis and Iron metabolism: data from in vivo studies. Meta. (2022) 12:89. doi: 10.3390/metabo12020089, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Jiang LT, Chen L, Yao SQ, Liu YL, Wen L. Analysis of factors influencing the occurrence of stress ulcers in patients with severe multiple trauma. Nurs Pract Res. (2024) 21:1650–6. [Google Scholar]
  • 52.Li B, Qiao P, Xiao ZZ. Predictive value of serum HSP70, HSP90 and GAS level in severe craniocerebral injury complicated with stress ulcer. J Pract Med. (2023) 39:48–53. [Google Scholar]
  • 53.Kivilaakso E. Pathogenetic mechanisms in experimental gastric stress ulceration. Scand J Gastroenterol Suppl. (1985) 110:57–62. doi: 10.3109/00365528509095833, [DOI] [PubMed] [Google Scholar]
  • 54.Hao ZH, Zhou DS, Zhang JL. Analysis of high risk elements related to stress ulcer following acute spinal cord injury. J Clin Orthoped. (2006):298–300. [Google Scholar]
  • 55.Wijeratne S, Chong C, Kirthinanda DS. Anaesthesiology perspective on a multidisciplinary approach to optimal perioperative management of a patient with giant peptic ulcer perforation caused by the physiological stress of a thyroid storm necessitating emergent laparotomy. BMJ Case Rep. (2022) 15:e250816. doi: 10.1136/bcr-2022-250816, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Hao XH, Chen YL, Li YC. Clinical diagnosis and treatment of diabetic ketoacidosis complicated by stress ulcer. Chinese Gen Pract. (2010) 13:274–6. [Google Scholar]
  • 57.Uhlenhopp DJ, Pagnotta G, Sunkara T. Acute esophageal necrosis: a rare case of upper gastrointestinal bleeding from diabetic ketoacidosis. Clin Pract. (2020) 10:1254. doi: 10.4081/cp.2020.1254, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Badipatla KR, Jadhav P, Vaddigiri S, Bajantri B, Singh A, Chandrala C, et al. Predictors of acute gastrointestinal bleeding in diabetic ketoacidosis: a retrospective observational study in minority population. Gastroenterol Rep (Oxf). (2017) 5:293–7. doi: 10.1093/gastro/gox006, [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.


Articles from Frontiers in Nutrition are provided here courtesy of Frontiers Media SA

RESOURCES